新型RNA递送纳米药物的结构-功能相关性研究

RAN Pub Date : 2017-04-01 DOI:10.11159/NDDTE17.118
Sara S. Nogueira, J. Moreno, H. Haas, K. Reuter, Stephanie Erbar, Peter Languth
{"title":"新型RNA递送纳米药物的结构-功能相关性研究","authors":"Sara S. Nogueira, J. Moreno, H. Haas, K. Reuter, Stephanie Erbar, Peter Languth","doi":"10.11159/NDDTE17.118","DOIUrl":null,"url":null,"abstract":"Extended Abstract Messenger RNA (mRNA)-based nanomedicines constitute a new class of pharmaceutical products, with a variety of potential applications, ranging from tumour immunotherapy to protein substitution. For patient administration, mRNA can be formulated in different types of nanoparticle vehicles, in order to protect the mRNA from degradation and facilitate uptake resulting in expression at the target site. BioNTech has brought the first intravenously injectable mRNA nanoparticle product for cancer immunotherapy into clinical trials, which consist of a lipoplex formulation obtainable from cationic liposomes [1, 2]. Lipid nanoparticles (LNPs) are another type of delivery vehicle and have been successfully used in the past, for example, to deliver siRNA to the liver [3]. Recently, LNPs have been also been used as carriers for mRNA, for induction potent CD8 T cell immune response [4], showing that LNPs can be versatile delivery systems for RNA in diverse therapeutic settings. Typically, LNPs are comprised of an ionizable lipid, one or several helper lipids and a polyethylene glycol (PEG). The ionizable lipid, which is positively charged at low pH and neutral at high pH, is selected to allow high RNA encapsulation and efficacy and to facilitate endosomal escape. The activity of the mRNA LNP formulations strongly depends on the type of ionisable lipid, on the lipid composition, the lipid to RNA ratio, and several other molecular and structural parameters. Furthermore, the activity may vary also for different application routes (e.g., intravenous, intramuscular, subcutaneous), or if therapeutic approaches are intended. So far, there is no clear common understanding on the correlation between the molecular parameters of the LNPs and the biological activity. Therefore, in our study we have systematically studied certain molecular and formulation parameters of mRNA loaded LNPs, in order to correlate them with the biological function. In particular we have thoroughly investigated physicochemical characteristics (internal organization, fluidity, size) and the structure of the LNPs (in particular by small angle x-ray scattering) and determined the biological activity in vitro and in vivo. The structural and functional coherencies in the LNPs were compared in those of lipoplexes, and the effects of selected lipids were highlighted. Such understanding of the molecular basis of delivery complexes will help to identify criteria for the development of improved mRNA delivery vehicles for clinical development.","PeriodicalId":31009,"journal":{"name":"RAN","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Structure-Function Correlation in Novel Nanomedicines for RNA Delivery\",\"authors\":\"Sara S. Nogueira, J. Moreno, H. Haas, K. Reuter, Stephanie Erbar, Peter Languth\",\"doi\":\"10.11159/NDDTE17.118\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Extended Abstract Messenger RNA (mRNA)-based nanomedicines constitute a new class of pharmaceutical products, with a variety of potential applications, ranging from tumour immunotherapy to protein substitution. For patient administration, mRNA can be formulated in different types of nanoparticle vehicles, in order to protect the mRNA from degradation and facilitate uptake resulting in expression at the target site. BioNTech has brought the first intravenously injectable mRNA nanoparticle product for cancer immunotherapy into clinical trials, which consist of a lipoplex formulation obtainable from cationic liposomes [1, 2]. Lipid nanoparticles (LNPs) are another type of delivery vehicle and have been successfully used in the past, for example, to deliver siRNA to the liver [3]. Recently, LNPs have been also been used as carriers for mRNA, for induction potent CD8 T cell immune response [4], showing that LNPs can be versatile delivery systems for RNA in diverse therapeutic settings. Typically, LNPs are comprised of an ionizable lipid, one or several helper lipids and a polyethylene glycol (PEG). The ionizable lipid, which is positively charged at low pH and neutral at high pH, is selected to allow high RNA encapsulation and efficacy and to facilitate endosomal escape. The activity of the mRNA LNP formulations strongly depends on the type of ionisable lipid, on the lipid composition, the lipid to RNA ratio, and several other molecular and structural parameters. Furthermore, the activity may vary also for different application routes (e.g., intravenous, intramuscular, subcutaneous), or if therapeutic approaches are intended. So far, there is no clear common understanding on the correlation between the molecular parameters of the LNPs and the biological activity. Therefore, in our study we have systematically studied certain molecular and formulation parameters of mRNA loaded LNPs, in order to correlate them with the biological function. In particular we have thoroughly investigated physicochemical characteristics (internal organization, fluidity, size) and the structure of the LNPs (in particular by small angle x-ray scattering) and determined the biological activity in vitro and in vivo. The structural and functional coherencies in the LNPs were compared in those of lipoplexes, and the effects of selected lipids were highlighted. Such understanding of the molecular basis of delivery complexes will help to identify criteria for the development of improved mRNA delivery vehicles for clinical development.\",\"PeriodicalId\":31009,\"journal\":{\"name\":\"RAN\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RAN\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11159/NDDTE17.118\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RAN","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11159/NDDTE17.118","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

基于信使RNA (mRNA)的纳米药物构成了一类新的药物产品,具有多种潜在的应用,从肿瘤免疫治疗到蛋白质替代。对于患者给药,mRNA可以在不同类型的纳米颗粒载体中配制,以保护mRNA免受降解并促进摄取,从而在靶部位表达。BioNTech已经将首个用于癌症免疫治疗的静脉注射mRNA纳米颗粒产品带入临床试验,该产品由阳离子脂质体制成的脂质体组成[1,2]。脂质纳米颗粒(LNPs)是另一种类型的递送载体,在过去已被成功使用,例如,将siRNA递送到肝脏。最近,LNPs也被用作mRNA的载体,用于诱导有效的CD8 T细胞免疫反应[4],这表明LNPs可以在不同的治疗环境中作为RNA的通用递送系统。LNPs通常由一种可电离脂质、一种或几种辅助脂质和聚乙二醇(PEG)组成。选择在低pH值下带正电而在高pH值下带中性电的可电离脂质,以实现高RNA包封和效率,并促进内体逃逸。mRNA LNP制剂的活性在很大程度上取决于可电离脂质的类型、脂质的组成、脂质与RNA的比例以及其他一些分子和结构参数。此外,活性也可能因不同的应用途径(例如,静脉注射、肌肉注射、皮下注射)或治疗途径而变化。到目前为止,LNPs的分子参数与生物活性之间的关系还没有明确的共识。因此,在我们的研究中,我们系统地研究了mRNA负载LNPs的某些分子和配方参数,以便将它们与生物学功能联系起来。特别是,我们深入研究了LNPs的物理化学特性(内部组织,流动性,大小)和结构(特别是通过小角度x射线散射),并确定了体外和体内的生物活性。比较了脂丛中LNPs的结构和功能一致性,并重点介绍了所选脂质的作用。这种对递送复合物分子基础的理解将有助于确定用于临床开发的改进mRNA递送载体的开发标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Structure-Function Correlation in Novel Nanomedicines for RNA Delivery
Extended Abstract Messenger RNA (mRNA)-based nanomedicines constitute a new class of pharmaceutical products, with a variety of potential applications, ranging from tumour immunotherapy to protein substitution. For patient administration, mRNA can be formulated in different types of nanoparticle vehicles, in order to protect the mRNA from degradation and facilitate uptake resulting in expression at the target site. BioNTech has brought the first intravenously injectable mRNA nanoparticle product for cancer immunotherapy into clinical trials, which consist of a lipoplex formulation obtainable from cationic liposomes [1, 2]. Lipid nanoparticles (LNPs) are another type of delivery vehicle and have been successfully used in the past, for example, to deliver siRNA to the liver [3]. Recently, LNPs have been also been used as carriers for mRNA, for induction potent CD8 T cell immune response [4], showing that LNPs can be versatile delivery systems for RNA in diverse therapeutic settings. Typically, LNPs are comprised of an ionizable lipid, one or several helper lipids and a polyethylene glycol (PEG). The ionizable lipid, which is positively charged at low pH and neutral at high pH, is selected to allow high RNA encapsulation and efficacy and to facilitate endosomal escape. The activity of the mRNA LNP formulations strongly depends on the type of ionisable lipid, on the lipid composition, the lipid to RNA ratio, and several other molecular and structural parameters. Furthermore, the activity may vary also for different application routes (e.g., intravenous, intramuscular, subcutaneous), or if therapeutic approaches are intended. So far, there is no clear common understanding on the correlation between the molecular parameters of the LNPs and the biological activity. Therefore, in our study we have systematically studied certain molecular and formulation parameters of mRNA loaded LNPs, in order to correlate them with the biological function. In particular we have thoroughly investigated physicochemical characteristics (internal organization, fluidity, size) and the structure of the LNPs (in particular by small angle x-ray scattering) and determined the biological activity in vitro and in vivo. The structural and functional coherencies in the LNPs were compared in those of lipoplexes, and the effects of selected lipids were highlighted. Such understanding of the molecular basis of delivery complexes will help to identify criteria for the development of improved mRNA delivery vehicles for clinical development.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
RAN
RAN
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信